Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 114,998 shares at $32.71 ($3.7M) on 2024-01-31, disclosed to the SEC on 2024-02-02.
Scheduled sale ($3.7M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.16 | 37,769 | $1.2M | 32.7% |
| 2 | $32.16 | 37,769 | $1.2M | 32.7% |
| 3 | $32.71 | 19,730 | $645K | 17.3% |
| 4 | $32.71 | 19,730 | $645K | 17.3% |
| Total | $32.35 avg | 114,998 | $3.7M | 100% |
| Filing → |
| ARWR | SELL | 2025-12-23 | $3.5M | — | Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |